ArticleiScience2026
HopRatio: Profiling single-sample transcriptomic dysregulation using stable gene-ordering relationships.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Single-sample transcriptomic analysis can provide gene-level views of how individual tumors deviate from matched reference states, complementing cohort-level differential expression. Here, we present HopRatio, a rank-based framework that quantifies, for each gene in each sample, the fraction of stable reference gene-ordering relationships inverted relative to a context-matched reference cohort. By relying on within-sample ranks rather than cross-sample expression magnitudes, HopRatio enables sample-specific scoring without cross-sample normalization for score calculation. Across 16 cancer types from The Cancer Genome Atlas with tissue-matched Genotype-Tissue Expression references, HopRatio generated individualized dysregulation profiles that supported tumor-normal discrimination using single genes and compact multi-gene panels. Recurrent high-performing features defined a 246-gene set enriched for developmental, membrane-associated, and ion-transport programs and associated with poor survival across cancers. Benchmarking in the Sequencing Quality Control dataset supported its robustness relative to commonly used differential expression methods, highlighting a scalable route for interpretable individualized transcriptomic analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.